Mario Roncadin

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Jayant S. Vaidya, Frederik Wenz, Max Bulsara et al. · The Lancet · 2013 · 832 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

Jayant S. Vaidya, David Joseph, Jeffrey Tobias et al. · The Lancet · 2010 · 763 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 565 citations

Medicine, Oncology, Surgery +17

Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation and Invasion Caused by Surgical Wounding

Barbara Belletti, Jayant S. Vaidya, Sara D’Andrea et al. · Clinical Cancer Research · 2008 · 232 citations

Medicine, Oncology, Surgery +17

Long-Term Results of Targeted Intraoperative Radiotherapy (Targit) Boost During Breast-Conserving Surgery

Jayant S. Vaidya, Michael Baum, Jeffrey Tobias et al. · International Journal of Radiation Oncology*Biology*Physics · 2010 · 140 citations

Medicine, Radiation Oncology, Surgery +16